So without getting into how the mechanism works I think the key thing is it’s a unique mechanism and the unique mechanism is such a way that you treat the tumour to teach the immune system to recognize what’s wrong with the cancer and UE use the lesion while you inject Allovectin as a classroom and that classroom is really teaching the immune system. Some immune systems learn very quickly, some immune systems take about 8, 10, 12 months before they learn. And that learning of the immune system is breaking of tolerance or teaching the immune system to recognize what’s wrong with that tumor getting it to recognize the markers that the cancer cell presents on the surface telling the immune system kill me, okay.
The most important thing is the newly approved drug therapy, immunotherapy Yervoy which is known as CTLA mAb. In animal studies we’ve shown that we’ve synergy with our therapy, a combination of Allovectin and CTLA mAb actually did better than CTLA mAb alone, so if this translates into human our drug that immunotherapy should have synergistic affects. So Vijay what’s the data.
Well Phase 2 trial which we did on 127 patients it’s a single-arm open-label study pretty large for a single-arm open-label study. 50% of the patients where stage 3, 50 % of those patients were stage 4, the key thing is the patients did not have brain mets and liver mets why? Because patients with brain mets and liver mets die very quickly and immunotherapy in order for the patient to benefit, they need to live long enough. What did we accomplish in that study we demonstrated first of all the drug was safe and efficacious, that’s key.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts